William Blair analyst Andrew Brackmann has maintained their bullish stance on SERA stock, giving a Buy rating yesterday.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Andrew Brackmann has given his Buy rating due to a combination of factors including Sera Prognostics’ progress in Medicaid pilot programs and their strategic steps towards increasing the adoption of their PreTRM test. The company is actively working on establishing a foundation for broader market penetration by focusing on coverage and reimbursement strategies, clinician awareness campaigns, and building a commercial team.
Brackmann also highlights the significance of the upcoming PRIME study publication, which is expected to provide additional data supporting future reimbursement and uptake. Although an increase in revenue and test volumes may take some time, the groundwork being laid by Sera Prognostics is seen as a positive indicator for future growth and market opportunity, justifying the Buy rating.
According to TipRanks, Brackmann is a 5-star analyst with an average return of 32.3% and a 68.09% success rate. Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Hologic, and QuidelOrtho.